Patient outcomes
| Engraftment (n, %) | |
| Yes | 143 (88%) |
| No | 20 (12%) |
| Myeloid chimerism at 2 years (avg) | 81.1% (range, 0%-100%) |
| GVHD (n, %) | |
| acute GVHD | 22 (13%) |
| chronic GVHD | 13 (8%) |
| Number of VOE (average [range], events per 100 patient-years) | |
| All participants (N = 163) | |
| 2 y before transplant | 5.6 (0-52), 1.7 |
| 0-12 mo after transplant | 0.8 (0-12), 0.5 |
| 12-24 mo after transplant | 0.1 (0-8), 0.06 |
| Engrafted participants (N = 143) | |
| 2 y before transplant | 5.6 (0-52), 1.7 |
| 0-12 mo after transplant | 0.8 (0-12), 0.5 |
| 12-24 mo after transplant | 0.03 (0-3), 0.02 |
| Rejected participants (N = 20) | |
| 2 y before transplant | 6.6 (0-24), 2 |
| 0-12 mo after transplant | 1.1 (0-6), 0.7 |
| 12-24 mo after transplant | 0.8 (0-8), 0.5 |
| Participants with GVHD (N = 31) | |
| 2 y before transplant | 3.5 (0-23), 1.1 |
| 0-12 mo after transplant | 0.1 (0-1), 0.06 |
| 12-24 mo after transplant | 0 (0), 0 |
| Engraftment (n, %) | |
| Yes | 143 (88%) |
| No | 20 (12%) |
| Myeloid chimerism at 2 years (avg) | 81.1% (range, 0%-100%) |
| GVHD (n, %) | |
| acute GVHD | 22 (13%) |
| chronic GVHD | 13 (8%) |
| Number of VOE (average [range], events per 100 patient-years) | |
| All participants (N = 163) | |
| 2 y before transplant | 5.6 (0-52), 1.7 |
| 0-12 mo after transplant | 0.8 (0-12), 0.5 |
| 12-24 mo after transplant | 0.1 (0-8), 0.06 |
| Engrafted participants (N = 143) | |
| 2 y before transplant | 5.6 (0-52), 1.7 |
| 0-12 mo after transplant | 0.8 (0-12), 0.5 |
| 12-24 mo after transplant | 0.03 (0-3), 0.02 |
| Rejected participants (N = 20) | |
| 2 y before transplant | 6.6 (0-24), 2 |
| 0-12 mo after transplant | 1.1 (0-6), 0.7 |
| 12-24 mo after transplant | 0.8 (0-8), 0.5 |
| Participants with GVHD (N = 31) | |
| 2 y before transplant | 3.5 (0-23), 1.1 |
| 0-12 mo after transplant | 0.1 (0-1), 0.06 |
| 12-24 mo after transplant | 0 (0), 0 |
GVHD, graft-vs-host disease; VOE, vaso-occlusive event.